Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Cincinnati Financial Corporation (CINF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Cincinnati Financial Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Cincinnati Financial Corporation trades at $183.26 (market cap $29.25B). The key difference: Cincinnati Financial Corporation is far larger — about 6.5× ACADIA Pharmaceuticals Inc.'s market cap, and Cincinnati Financial Corporation pays a 1.99% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | CINF | |
|---|---|---|
Market Cap | $4.49B | $29.25B |
Sector | Health | Financials |
52-Week High | $28.06 | $192.03 |
52-Week Low | $20.06 | $145.80 |
Enterprise Value | $3.69B | $28.92B |
Dividend Yield | — | 1.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Cincinnati Financial (CINF) trades at $189.06, down 1.55% on the day, but remains near its 52-week high. The stock shows strong fundamental performance with consistent earnings beats, a low P/E of 10.84, and robust profitability metrics including an 18.73% ROE. Recent technical indicators are mixed, with moving averages bullish but oscillators signaling overbought conditions. The company maintains a solid dividend track record, recently declaring a $0.94 dividend payable in July 2026.
CINF presents a compelling investment case supported by strong earnings growth, attractive valuation, and positive analyst sentiment, though near-term technical overbought signals and exposure to catastrophe losses pose risks. The consensus price target of $183.25 suggests limited upside from current levels, but long-term fundamentals remain sound.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →
